Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

2.99
-0.2600-8.00%
Pre-market: 2.97-0.0200-0.67%06:44 EDT
Volume:2.20M
Turnover:6.94M
Market Cap:286.14M
PE:-3.29
High:3.36
Open:3.19
Low:2.99
Close:3.25
52wk High:11.46
52wk Low:1.07
Shares:95.70M
Float Shares:72.51M
Volume Ratio:0.33
T/O Rate:3.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9078
EPS(LYR):-0.9791
ROE:-74.02%
ROA:-44.09%
PB:2.24
PE(LYR):-3.05

Loading ...

Why Is XOMA Royalty Stock Sinking Thursday?

Benzinga_recent_news
·
Dec 12, 2025

Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial

Benzinga_recent_news
·
Dec 12, 2025

Top Midday Stories: Oracle Shares Tumble After Revenue Miss; Lilly's Next-Gen Weight-Loss Drug Hits Primary Endpoints

MT Newswires Live
·
Dec 12, 2025

Wedbush Downgrades Rezolute to Neutral From Outperform, Price Target is $1

MT Newswires Live
·
Dec 11, 2025

Rezolute Shares Plummet After Phase 3 Trial Fails to Meet Goals

Dow Jones
·
Dec 11, 2025

Rezolute Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $1 From $12

THOMSON REUTERS
·
Dec 11, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill

Reuters
·
Dec 11, 2025

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires Live
·
Dec 11, 2025

Rezolute Exec Says Nothing Heard From FDA Related to Congenital Study Impacting Tumor Study

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says Two Patients Who Discontinued Due to Serious Hypersensitivity Reactions Did Not Have Positive Anti-Drug Antibodies - Conf Call

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says FDA Discussion Will Be Completely Focused on Congenital Indication

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says of 63 Enrolled Participants, Four Patients Early Terminated Study Due to Adverse Events

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says More Than 50 Patients Still on Open Label Extension Study

THOMSON REUTERS
·
Dec 11, 2025

BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism

Reuters
·
Dec 11, 2025

Rezolute Shares Fall 91.3% Premarket After Rare Disease Drug Fails to Meet Main Goal in Late-Stage Study

THOMSON REUTERS
·
Dec 11, 2025

Rezolute's rare disease drug fails main goal in late-stage trial

Reuters
·
Dec 11, 2025

Rezolute’s Phase 3 sunRIZE Trial of Ersodetug in Congenital Hyperinsulinism Misses Primary Endpoint

Reuters
·
Dec 11, 2025

Rezolute Inc - Phase 3 Study Fails to Meet Primary Endpoint

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Inc: Phase 3 Uplift Study for Tumor Hi Is Ongoing With Topline Results Expected in Second Half of 2026

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Inc: Announces Phase 3 Sunrize Study Results in Congenital Hyperinsulinism

THOMSON REUTERS
·
Dec 11, 2025